Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Church & Dwight Co., Inc. (CHD) Price & Performance

Amgen, Inc.Trade
Church & Dwight Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Church & Dwight Co., Inc. — how do they compare? Amgen, Inc. trades at $413.37 (market cap $225.71B), while Church & Dwight Co., Inc. trades at $102.84 (market cap $24.50B). The key difference: Amgen, Inc. is far larger — about 9.2× Church & Dwight Co., Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

AMGNCHD
Market Cap
$225.71B$24.50B
Sector
HealthConsumer Staples
52-Week High
$417.20$105.26
52-Week Low
$271.18$81.60
Enterprise Value
$269.02B$26.50B
Dividend Yield
2.42%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.

Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.

Church & Dwight Co., Inc.

Church & Dwight (CHD) trades at $103.24, slightly below the consensus price target of $103.57, with a modest 24-hour decline of 0.12%. The stock exhibits a bullish technical trend, supported by moving averages, while fundamentals show steady revenue growth to $6.20 billion in 2025 and a net income margin of 11.96%. Recent Q2 2026 earnings matched estimates with organic sales growth of 5.8%, prompting raised full-year guidance. Analyst sentiment is positive with 53% buy ratings, though valuation multiples like a P/E of 33.09 suggest premium pricing.

The outlook remains favorable due to strong brand performance and raised earnings guidance, but risks include elevated debt levels and competitive pressures in consumer staples. Institutional activity shows mixed positions, with some funds reducing stakes. The stock's upside is capped by high valuations, requiring sustained earnings growth to justify current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Church & Dwight Co., Inc.

Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.

Read more on CHD